News | June 03, 2026
Intracin Pharma secures APVMA nod to supply veterinary medicines in Australia
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
Derived from rice bran wax, Licocare RBW products offer a renewable solution with a substantially lower carbon footprint than conventional montan waxes
The approval marks a major milestone in the global fight against antimicrobial resistance
Crucially, Lupin is the exclusive first-to-file applicant for this product and is eligible for 180-day generic drug exclusivity in the U.S. market
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients
Clearance marks major shift beyond chemotherapy
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)
Subscribe To Our Newsletter & Stay Updated
